Retrotope Company

Retrotope creates a new category of drug platform to preserve and restore mitochondrial health in degenerative diseases. It is a privately held company focused on the development of ways of controlling metabolic processes associated with oxidative stress conditions. Retrotope uses isotope effect to slow down damaging pathways. The company hasseveral discovery and development programs that involve major classes of biopolymers, with the major focus on neurological diseases such as Friedreich's ataxia.
Technology: Cancer
Industry: Small&Large Molecules
Headquarters: Los Altos Hills, California, United States
Founded Date: 1/1/2006
Employees Number: 11-50
Funding Status: Late Stage Venture
Investors Number: 19
Total Funding: €322.9M
Estimated Revenue: Less than $1M
Last Funding Type: Grant

Visit Website
Register and Claim Ownership